Dr Satu Vainikka, CEO commented:

"I am delighted that we are now launching our Chlamydia self-testing product into the UK and Irish markets. With Chlamydia being diagnosed as the fastest growing sexually transmitted disease at the moment, our self-testing pack, as an affordable, easy -to-use and rapid indicator of the presence or absence of the Chlamydia bacterium has the potential to become a first line test against Chlamydia. With the disease having the potential to affect fertility in both sexes, I particularly urge young people looking to start a family to test themselves early. Early detection will mean early intervention and thinking that there is not a problem is just not thinking."

Broker Hybridan was positive about the launch, stating that ValiRx remains far from fully valued at these levels.

We like the model of product on the market generating revenues in the test kits and the more blue sky upside that its proprietary drug development programmes provide in the technology platform, said Hybridan.

Last month, ValiRx completed the sale of its Belgian diagnostic development business, ValiBIO SA, to Singapore Volition Pte Ltd, having received all the funds it was due.

ValiRx continues to retain its significant shareholding in Volition and in the future upside value and growth of the business and integration between the companies is progressing well

http://www.proactiveinvestors.co.uk/companies/news/25504/valirx-aim-stock-out-of-the-doldrums-25504.html

glad it ended higher than .1 - it was looking that way at times - but no way should anyone have bought at 2.3 - i was in and top sliced which i thought most would - i am going to keep my remaining holding as i consider this a very interesting share - it has been on my radar for a while as many others have - this chlamydia self test has imo huge potential and high profit margin - and is cheaper & quicker than current methods availble either through NHS or elsewhere (although i have heard there is a european competitor that i have not had time to evaluate / comfirm) and for those embarrased saves a visit to a STD clinic - it is early days but i am hoping for a multi bagger not just on the chlamydia self test but their other niche products - if any were and still are locked i should hold - my opinion is it may be back quicker than we may expect with i hope more for all - interesting 2011 ahead

http://www.investegate.co.uk/Article.aspx?id=201102160719213156B

http://www.proactiveinvestors.co.uk/companies/news/25580/valirx-after-the-storm-money-in-the-bank-and-a-strong-product-in-the-shops-25580.html

ValiRx

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
Tweet Share ValiRx after the storm: money in the bank and a strong product in the shops
Wednesday, February 16, 2011 by Andre Lamberti The money raised today will be used to accelerate the pre-clinical progress of its lead therapeutics VAL101 and 201 ValiRx PLC (LON:VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, said its broker Hybridan LLP has conditionally raised 3.3 million before expenses through a placing of 549.5 million new shares at a price of 0.6 pence each.

The money will be used to accelerate the pre-clinical progress of its lead therapeutics VAL101 and 201.

VAL 101 is a compound undergoing development that silences a gene which - in a mutated form - renders chemotherapy less effective. ValiRx believes the compound could be effective particularly in the treatment of breast and prostate cancer as well as leukaemia.

The company is also evaluating a novel peptide for treatment of refractory prostate cancer. A drug compound, dubbed VAL201, based on the peptide has the potential of becoming a significant treatment option for patients exhibiting androgen independent prostate cancer.

In pre-clinical studies, the peptide has shown to be highly effective against prostate and breast cancer, ValiRx said.

The group has had its fair share of excitement lately. Its share price started to rise last week from just under 0.30 pence a share, a level it had held pretty much constantly for the last part of 2010 and into the new year.

And things went slightly crazy on Monday, when investors piled into the stock after the group announced the launch of its Chlamydia SELFCheck over-the-counter health screening product in the UK. The stock hit an intraday high of 0.79p at one point.

Yesterday the rollercoaster ride continued with the stock peaking above 2.5 pence at one point before giving back a lot of its enormous gains during the remainder of the session.

Under the circumstances, the strong fall today in response to the fundraising must be put in perspective: shareholders who held the stock less than a week ago have still made a profit of nearly 150 percent.

Following the storm, ValiRx appears to be in a good position: it now has an over-the-counter chlamydia test kit in the shops that enables women to test at home and get a result in 10 minutes, rather than wait 4-5 days to get the result from a laboratory; and it has money in the bank to progress two compounds with the potential to be used in treating some of the most common cancers

imo catch this minnow cheap while you can.....

A kit on the side

A NEW DIY testing kit for sex disease Chlamydia has been launched - on Valentine's Day.

London-based VALIRX said the over-the-counter product for women reveals results in ten minutes. Shares soared by 205 PER CENT - or 1.11p - to 1.65.

The global market for such testing kits is expected to soar 40 per cent to 11.6billion by 2014. A tenth of 20-year-old women in Europe are thought to be infected with Chlamydia.................

and 6 other fully funded projects

better long term than short term here

lol - 2.5m buy.........

need to read rns links

RNS Number : 5082B

ValiRx PLC

18 February 2011

ValiRx Plc

("ValiRx" or the "Company")

Publication of Circular and Notice of General meeting

Further to the announcement made by the Company on 16 February 2011, the board announces that a circular has been published convening a general meeting of the Company to be held on 7 March 2011 at 10.00 a.m. at the offices of Nabarro LLP at Lacon House, 84 Theobald's Road, London WC1X 8RW at which the directors are seeking to increase the share authorities of the Company.

The circular may be downloaded from the Company's website at www.valirx.com.

A letter has been sent to those shareholders who have agreed to receive documents via the Company's website notifying them that the circular is available on the Company's website and enclosing the form of proxy for use at the general meeting.

For more information, please contact:

ValiRx Plc www.valirx.com

Dr. Satu Vainikka Tel: +44 (0) 20 3008

4416

Hybridan LLP - Broker

Claire Noyce Tel: +44 (0) 207 947

4350

from the other side..................

VALIRX/VAL

HYBRIDAN,recieved an email from the house broker HYBRIDAN they will be releasing an new note and article imminently they kept it back from last nights as its a full UPGRADE.

http://www.proactiveinvestors.co.uk/columns/hybridan-small-cap-wrap/4625/animalcare-purrs-along-lo-q-moves-forward-magnesium-hydroxide-is-a-sirius-by-product-and-encore-soon-to-repeat--4625.html

think i need to go to a meeting - lol! also looking fwd to the q&a he mentions below to appear on val www

From: Gerry Desler
To: Gerry Desler
Sent: Thursday, February 24, 2011 5:xx PM
Subject: ValiRx Plc


Dear Shareholder



Thank you very much for your email and your ongoing support and interest in ValiRx.



The company has had a large number of enquiries this week on several subjects and the Board has decided that in order to answer them in a timely manner to post onto the Companys web-site a selection of Q & As.



We look forward to continued dialogue with our shareholders and can take and answer further questions at our upcoming General Meeting.



Many thanks again for the continued support.





Gerry Desler

Director

lol - rns ref my email above lol!!!! you should read this - val is going places and sp will continue north - yeeeeeeeeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aroooooooooooooooooooooooooooooooooooooooooooooooooooooo!!!


check their www...............

http://www.londonstockexchange.com/exchange/news/dow-jones/news-detail.html?newsId=20110225SN006380

Other Group Sites Academy BIt Club Borsa Italiana CC & G EDX London London Stock Exchange Group Market Connect MillenniumIT Monte Titoli MTS Group Palazzo Mezzanotte Proquote Servizio Titoli Turquoise View Portfolio Login Forgotten Password? Home Prices and markets News and finance Statistics Products and services For traders and brokers For companies and advisers For specialist issuers Press Association Dow Jones ShareCast Personal Finance Focus On Specials Private investors RNS
Home page News and finance Dow Jones


www.dowjones.com
Dow Jones Newswires
Date Select Today Yesterday Last week | From Select date To Select date

DJ ValiRx PLC Website Update
25 Feb 2011 - 14:09
TIDMVAL

RNS Number : 8988B

ValiRx PLC

25 February 2011

25 February 2011

ValiRx Plc

("ValiRx" or the "Company")

Website Update

The Company announces that it has today uploaded a document on its AIM Rule 26 website (www.valirx.com) responding to frequently asked questions received from shareholders in relation to its recent announcements on the launch of its chlamydia self-check health screening product (14 February 2011) and issue of equity (16 February 2011).

For more information, please contact:


ValiRx plc www.ValiRx.com
Dr Satu Vainikka Tel: +44 (0) 20 3008 4416

Cairn Financial Advisers LLP
Nominated Adviser Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson

Hybridan LLP
Broker Tel: +44 (0) 20 7947 4350
Claire Noyce

Peckwater PR Tel: +44 (0)7879 458 364
Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk

i would not wanna be outta val over the weekend lol lol!!!

I'm amazed at your stamina gibby, have a good rest from monday. Ha! Ha!
2517

cheers 2517 - that's the kinda person i am - lol! you have a good weekend - have to wind me down now!!

not a new article but worth keeping in mind while val is still relatively cheap before the next rns:

CRT and ValiRx sign prostate cancer treatment deal

16 August 2010

Cancer Research Technology has signed a deal to provide biotech company ValiRx PLC with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.

The compound, now called VAL 201, has been shown in preclinical tests in mice to stop the growth of tumours that have been unresponsive to hormone treatments. VAL 201 blocks genes that can cause prostate cancer to develop.

Hormone therapy will work for between eight and nine of every ten men with advanced-stage prostate cancer, but many men will become resistant to the treatment at some stage. This does not seem to be related to the length of time a man is receiving treatment.

VAL 201 has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

Under the terms of the deal, ValiRx has exclusive rights to use the compound to treat, prevent and diagnose cancer and other diseases. Cancer Research Technology Cancer Research UK's development and commercialization arm will receive milestone payments throughout the development and commercialization of the compound and royalty payments for potential licensed treatments.

Dr Phil LHuillier, Cancer Research Technologys director of business management, said: This partnership demonstrates CRTs ability to maximize its broad network, having identified and licensed this project from Naples, and then in turn partnered it for further preclinical and clinical development with ValiRx.

We will follow further trials to test its suitability as a new treatment to potentially increase survival from this disease with great interest.

Under the terms of the licence with Cancer Research Technology, ValiRx will be responsible for performing the preclinical regulatory development of VAL 201 to prepare the compound for early clinical trials in patients. ValiRx will manage the commercialization of potential treatments after clinical trials.

Currently, prostate cancer is the most common cancer among men: each year in the UK, 36,000 men are diagnosed with the disease and it causes approximately 10,150 deaths.

http://www.drugdiscoverytoday.com/view/11784/crt-and-valirx-sign-prostate-cancer-treatment-deal/

hmmmmmmmmmmm nice delayed buy today - 51m 0R APPROX 9%of company

Date Time Trade Prc Volume Buy /SellBidAsk Value (approx)
3-Mar-11 07:59:38 0.69 51,249,985 Buy* 0.65 0.66 353.62k

LOL!
glad in early here

from the other side....

'Broker note due out today / next week.

HPV tester due for launch early/mid 2011 - remember the spike from the Chlamydia tester?

AGM June 2011 - always a bit of movement on anticpation, also this year we have revenue streams coming forward!

GENEice pre-clinical results close 2011 - significance on a par with SAR imo

3.3M cash in the bank

Novel and commercially - focussed business model and BoD looking to improve shareholder value short term

10% rise over last 2 days

Currently sitting just above share issue effectively underwritten at .6

tiny market cap primed for growth

new driven.

these are just some of the +ives in my opinion. If you're nervous, average down, wait for news, set an RNS text alert, then come back then and sell-off when you've made some , which you will do. this company is not going to dissapear - so what's the panic?'

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=10808177

from jan but worth a reminder............

ValiRxSPECULATIVE BUY 21/01/2011 Ben Jaglom
Reduce text size Decrease text size Increase text size Increase text size Print article Print Share this article Share Email article to a friend Email HPV testing and cancer technology developer ValiRX (VAL) is hoping to boost its lowly share price over the coming years.

The London-headquartered concern has two parts to its business. There is ValiPharma, which is developing the GeneICE technology, a way of putting on ice cancer cells and which was developed by Imperial College, London and Cancer Research Technology, the commercial arm of cancer charity Cancer Research.

In addition there is a clinical testing division, which under the brand SELFcheck sells tests for a range of conditions including the menopause, female Chlamydia and stomach ulcers, with the kits sold to a range of retailers as well as directly online.

It is also currently developing a test for the sexually transmitted Human Papilloma Virus (HPV) a virus that can cause genital warts and cervical cancer.

Having come to AIM in 2006 the venture is led by Satu Vinikka, the Finnish CEO who was previously the CEO of Cronos Therapeutics, the spin out from Imperial College that was purchased by ValiRX in 2006.

Last December saw ValiRx provide an update on its progress with Eurostars. Eurostars is a grant scheme that provides funding for companies in the EU. ValiRx had received 1.2m (1m) in funding for its cancer drug GeneICE and the update came eighteen months into the deal, with ValiRx having now submitted the progress report necessary to obtain the next stage in funding.

House broker Hybridan is forecasting a loss of 507,482 on a turnover of 95,869 for the year to 2010, with profits not expected until 2012 when the broker is pencilling in a maiden profit of 774,823 on turnover of 1.4m.

A tiny company with a correspondingly tiny share price, shares in ValiRx are certainly not for widows and orphans. However with a relatively diversified business split between its GeneICE programme and its testing division, we think as a speculative investment the shares are certainly worth a punt.

worth a look today?

apparently news expected from US cancer conf
appeared to go very well

bought in this morning...worth a punt I reckon...up a little already!